1. Home
  2. Labeler Index
  3. Aurobindo Pharma Limited
  4. 59651-095
  5. Product Images: Silodosin

Product Images Silodosin

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 8 images provide visual information about the product associated with Silodosin NDC 59651-095 by Aurobindo Pharma Limited, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1 Mean (±SD) Silodosin Steady State Plasma Concentration-Time Profile in Healthy Target-Aged Subjects Following Silodosin 8 mg Once Daily with Food - silodosin fig1

Figure 1 Mean (±SD) Silodosin Steady State Plasma Concentration-Time Profile in Healthy Target-Aged Subjects Following Silodosin 8 mg Once Daily with Food - silodosin fig1

Figure 2 Mean Change from Baseline in IPSS Total Score by Treatment Group and Visit in Study 1 - silodosin fig2

Figure 2 Mean Change from Baseline in IPSS Total Score by Treatment Group and Visit in Study 1 - silodosin fig2

The text describes the change from baseline in IPSS Total Score for a medication called Siladosin 8 mg compared to the placebo, and displays the statistical significance of the result with a p-value of less than 0.0001. The text also includes some alphanumeric codes which are not clearly interpretable.*

Figure 3 Mean Change from Baseline in IPSS Total Score by Treatment Group and Visit in Study 2 - silodosin fig3

Figure 3 Mean Change from Baseline in IPSS Total Score by Treatment Group and Visit in Study 2 - silodosin fig3

The text describes the change from baseline in IPSS total score, with reference to a statistical significance of p<0.0001. However, without additional context or information, it is not possible to determine what the IPSS score represents, what the AAAPhcebo and iocosin 8 mg refer to, or what the B a5 7 and Day 84/LOCF signify.*

Figure 4 Mean Change from Baseline in Qmax (mL/sec) by Treatment Group and Visit in Study 1 - silodosin fig4

Figure 4 Mean Change from Baseline in Qmax (mL/sec) by Treatment Group and Visit in Study 1 - silodosin fig4

Figure 5 Mean Change from Baseline in Qmax (mL/sec) by Treatment Group and Visit in Study 2 - silodosin fig5

Figure 5 Mean Change from Baseline in Qmax (mL/sec) by Treatment Group and Visit in Study 2 - silodosin fig5

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 4 mg (30 Capsules Bottle) - silodosin fig6

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 4 mg (30 Capsules Bottle) - silodosin fig6

Silodosin Capsules 4mg, distributed by Aurobindo Pharma USA, Inc. in a bottle with 30 capsules. The usual dosage is one capsule taken orally once daily with a meal as per the packaging insert for full prescribing information. Made in India. Store the medication between 20°C to 25°C and protect from light and moisture. Keep out of reach of children. Not available for the purpose of the coding area.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 8 mg (30 Capsules Bottle) - silodosin fig7

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 8 mg (30 Capsules Bottle) - silodosin fig7

Each Silodosin capsule contains & mg which is a medicine distributed by Aurabindo Pharma USA. It is recommended to take the medicine once a day with a meal. For detailed prescribing information, please see the package insert. The medicine should be stored and dispensed in controlled room temperature and protected from light and moisture. The medicine is available in the form of 20/255/76/152 capsules. It is a prescription drug made in India. Keep out of reach of children.*

Silodosin Chemical Structure - silodosin str

Silodosin Chemical Structure - silodosin str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.